The C-WORTHY trial is a randomised , open-label phase @ trial of grazoprevir plus elbasvir with or without ribavirin ; here we report findings for two cohorts of previously untreated patients with cirrhosis ( cohort @ ) and those with previous PR-null response with or without cirrhosis ( cohort @ ) enrolled in part B of the study .